Evotec-partner Jingxin receives approval for EVT201 in China

  • Evotec SE announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd (“Jingxin”) has received the approval from the Chinese National Medical Products Administration (“NMPA”) for the novel insomnia treatment EVT201, also known as Dimdazenil in China.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-jingxin-receives-approval-for-evt201-in-china-6352

    Du magst vielleicht auch